Cat. No.: DAB-0011755
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Monkey |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human annexin A7. Antibodies are purified using protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ANXA7 |
| UniProt No. | P20073 |
| Gene ID | 310 |
| Gene Description | Annexin A7/ANXA7 is a member of the annexin family of calcium/phospholipid-binding proteins, and is involved in the process of membrane fusion and exocytosis. Annexin A7 is a GTPase, and both GTP-binding and PKC activity are important in regulating protein function. Membrane binding of annexin A7 is calcium dependent. Two isoforms exist due to alternative splicing. Subcellular localization of annexin A7 has been shown to be in the cytoplasm, vesicular structures, membrane and in adrenal chromaffin granules. Nuclear localization has been shown in the developing mouse central nervous system as well as in adult mouse brain. Annexin A7-deficient mouse studies show that the protein has a role in insulin secretion and calcium signaling as well as cardiac intracellular calcium homeostasis electrical stability. The gene for annexin A7 is a putative tumor suppressor, and alterations in the copy number have been reported in prostate cancer. Annexin A7 expression has also been correlated with survival in human glioblastoma patients, and haploinsufficiency in mice may promote genetic instability leading to tumorigenesis. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
